Paul A Goepfert MD
Professor, Medicine, University of Alabama School of Medicine
Join to view full profile
619 19th St SBirmingham, AL 35233
Phone+1 205-934-6600
Dr. Goepfert is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Alabama Hospital (Birmingham)Fellowship, Infectious Disease, 1994 - 1997- University of Alabama Medical CenterResidency, Internal Medicine, 1991 - 1994
Baylor College of MedicineClass of 1991
Certifications & Licensure
AL State Medical License 1992 - 2026
TX State Medical License 1992 - 1997
American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2013-2014, 2017
- CMS Meaningful Use Stage 1 Certification MyHealth@UABMedicine, UAB Health System, 2013-2014, 2017
- CMS Meaningful Use Stage 2 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2013-2014, 2017
Clinical Trials
- Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
- Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
- Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults
Publications & Presentations
PubMed
- CD151 identifies a cytotoxic CD4 T cell population enriched in people with HIV that later develop cancer.Mildred Perez, Fangming Zhu, Eric Carlin, Braxton D Greer, Andrew Schroeder
Journal of Immunology. 2026-08-04 - mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Ashwin N Skelly, Chengcheng Fan, Jennifer R Keeffe, Arya B Ökten, Edem Gavor
Proceedings of the National Academy of Sciences of the United States of America. 2026-06-16 - A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.James J Kobie, Wilton B Williams, William O Hahn, Paul T Edlefsen, Margaret Brewinski Isaacs
Medrxiv. 2026-05-27
Press Mentions
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27th, 2025- Memory B Cell Marker Predicts Long-Lived Antibody Response to Flu VaccineMarch 22nd, 2023
- Indians Remain Wary of Booster Doses as Covid Wanes and Side-Effect Worries RiseJanuary 17th, 2023
Grant Support
- Onco-immunologic factors contributing to OPSCC among people living with HIVUNIVERSITY OF ALABAMA AT BIRMINGHAM2024–2029
- A-Z Clinical Trials UnitUNIVERSITY OF ALABAMA AT BIRMINGHAM2007–2027
- Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responsesUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2025
- CTL And HIV Polymorphisms In Heterosexual TransmissionNational Institute Of Allergy And Infectious Diseases2010–2012
- HIV-1 Cryptic Epitopes: Implications For Vaccine DesignNational Institute Of Allergy And Infectious Diseases2009–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
